Ocugen Reports Q4 EPS of -$0.06, Posts Negative Operating Profit
OCGN has more than doubled off its 52-week low of $0.515.
Summary
Ocugen reported a Q4 EPS of -$0.06, alongside operating expenses of $16.802 million, a profit from operations of -$16.995 million, and a net income of -$17.706 million. This financial update provides a look into the company's burn rate following recent positive clinical news. The continued negative earnings and operating profit highlight the ongoing financial challenges for the development-stage biotechnology company. Traders will be assessing these results in the context of the company's cash position and future funding needs, especially as it progresses with its clinical pipeline.
At the time of this announcement, OCGN was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.9M. The 52-week trading range was $0.52 to $1.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.